Merck
  • Home
  • Search Results
  • Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication.

Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication.

Nature immunology (2021-03-27)
Haitao Guo, Qi Wang, Khader Ghneim, Li Wang, Elena Rampanelli, Elizabeth Holley-Guthrie, Liang Cheng, Carolina Garrido, David M Margolis, Leigh A Eller, Merlin L Robb, Rafick-Pierre Sekaly, Xian Chen, Lishan Su, Jenny P-Y Ting
ABSTRACT

Individuals infected with human immunodeficiency virus type-1 (HIV-1) show metabolic alterations of CD4+ T cells through unclear mechanisms with undefined consequences. We analyzed the transcriptome of CD4+ T cells from patients with HIV-1 and revealed that the elevated oxidative phosphorylation (OXPHOS) pathway is associated with poor outcomes. Inhibition of OXPHOS by the US Food and Drug Administration-approved drug metformin, which targets mitochondrial respiratory chain complex-I, suppresses HIV-1 replication in human CD4+ T cells and humanized mice. In patients, HIV-1 peak viremia positively correlates with the expression of NLRX1, a mitochondrial innate immune receptor. Quantitative proteomics and metabolic analyses reveal that NLRX1 enhances OXPHOS and glycolysis during HIV-1-infection of CD4+ T cells to promote viral replication. At the mechanistic level, HIV infection induces the association of NLRX1 with the mitochondrial protein FASTKD5 to promote expression of mitochondrial respiratory complex components. This study uncovers the OXPHOS pathway in CD4+ T cells as a target for HIV-1 therapy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Doxycycline hydrochloride
Sigma-Aldrich
Rotenone, ≥95%
Sigma-Aldrich
Resveratrol, ≥99% (HPLC)
Sigma-Aldrich
2-Deoxy-D-glucose, ≥98% (GC), crystalline
Supelco
Metformin hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material